10times
13 Oct 2020Ended

Biosimilars: What Employers Should Know and Why They Should Act

AboutSpeakersExhibitorsReviewsPhotos

Estimated Turnout

upto 100
Delegates
Based on previous editions

Editions

13 Oct 2020

Frequency

Not Available
Claim event to edit details

D., Senior Fellow, Business and Economics, Pacific Research Institute; Director, Center for Medical Economics and Innovations, PRI’ Principle, .. Read more Capital Economic Advisors. Biologics are complex cutting-edge medicines that treat diseases such as cancer, arthritis, and auto-immune diseases. These innovative products, known as originator biologics, create tremendous value for patients. Biosimilars, medicines that have the same quality, safety, and efficacy as the originator biologic, are akin to generic medicines for the biologics market. Learning Objectives: - Demonstrate how employers can achieve greater out-of-pocket savings for employee patients by using biosimilars instead of originator biologic medicines - Overview of costs associated with patients being treated with biologic medicines for cancer, arthritis and autoimmune disease. - Current state of biosimilar market For Health ACtion Council Members only 1 SHRM and 1 HRCI credit pending.

  • Share your Experience
  • Organizer
Logo Follow Company

Health Action Council Ohio

USA 8 Total Events / 2 Upcoming Events

More Events From The Organizer